Confo Therapeutics Taps AbCellera for GPCR-Targeting Antibody Discovery
Portfolio Pulse from Benzinga Newsdesk
Confo Therapeutics has entered into a research collaboration with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. Confo will apply its ConfoBody technology and be entitled to upfront payments, milestones, and tiered royalties on net product sales.
June 15, 2023 | 9:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbCellera partners with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting GPCR targets, potentially expanding its product pipeline.
The partnership with Confo Therapeutics will allow AbCellera to expand its product pipeline by discovering therapeutic antibody candidates targeting GPCR targets. This collaboration could lead to potential revenue growth through upfront payments, milestones, and tiered royalties on net product sales, positively impacting AbCellera's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80